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Background: APC mutations (APC-mt) occur inB70% of colorectal cancers (CRCs), but their relationship to prognosis is unclear.
Methods: APC prognostic value was evaluated in 746 stage I–IV CRC patients, stratifying for tumour location and microsatellite
instability (MSI). Microarrays were used to identify a gene signature that could classify APC mutation status, and classifier ability to
predict prognosis was examined in an independent cohort.
Results: Wild-type APC microsatellite stable (APC-wt/MSS) tumours from the proximal colon showed poorer overall and
recurrence-free survival (OS, RFS) than APC-mt/MSS proximal, APC-wt/MSS distal and APC-mt/MSS distal tumours (OS HRX1.79,
Pp0.015; RFS HRX1.88, Pp0.026). APC was a stronger prognostic indicator than BRAF, KRAS, PIK3CA, TP53, CpG island
methylator phenotype or chromosomal instability status (Pp0.036). Microarray analysis similarly revealed poorer survival in MSS
proximal cancers with an APC-wt-like signature (P¼ 0.019). APC status did not affect outcomes in MSI tumours. In a validation on
206 patients with proximal colon cancer, APC-wt-like signature MSS cases showed poorer survival than APC-mt-like signature MSS
or MSI cases (OS HRX2.50, Pp0.010; RFS HRX2.14, Pp0.025). Poor prognosis APC-wt/MSS proximal tumours exhibited features
of the sessile serrated neoplasia pathway (Pp0.016).
Conclusions: APC-wt status is a marker of poor prognosis in MSS proximal colon cancer.
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Colorectal cancer (CRC) is a leading cause of cancer-related death
in the Western world (Stewart and Wild, 2014). Despite advances
in surgery and oncology, the average 5-year survival rate remains
below 60%. Treatment decisions are primarily based on disease
staging performed by imaging and tumour histopathological
assessment. However, there exists substantial heterogeneity in
prognosis within tumours of identical stage.
Approximately 70% of sporadic CRCs are initiated by biallelic
inactivation of the APC tumour-suppressor gene, resulting in
aberrant activation of WNT/b-catenin signalling (Christie et al,
2013). The majority of APC-mutated (APC-mt) cancers are
thought to develop via the classic adenoma-carcinoma pathway,
characterised by premalignant adenomatous polyps with tubular
and/or villous architecture, and carcinomas associated with TP53
mutation and chromosomal instability (CIN) (Fearon and
Vogelstein, 1990). Another major pathway to CRC is the sessile
serrated pathway, accounting for 15–20% of cases (Leggett and
Whitehall, 2010; Snover, 2011; Bettington et al, 2013). This
pathway is typified by precursor sessile serrated adenomas, wild-
type APC (APC-wt), BRAF mutation, a CpG island methylator
phenotype (CIMP-high), poor differentiation and mucinous
histology, and approximately half of sessile serrated pathway
cancers show late development of microsatellite instability (MSI).
A further alternate pathway has been proposed, perhaps compris-
ing 5–10% of CRC, which may arise from traditional serrated or
tubulovillous adenomas and exhibits CIMP-low, KRAS and
PIK3CA mutation and a microsatellite stable (MSS) genotype
(Leggett and Whitehall, 2010; Day et al, 2013). Notably, these
pathways show differential distributions throughout the large
intestine, with the sessile serrated pathway more frequent in the
proximal colon, and the classic pathway more common in the
distal colon and rectum.
Individual molecular characteristics associated with the neopla-
sia pathways including CIN, MSI, CIMP and mutations in KRAS,
BRAF, PIK3CA and TP53 have all been evaluated as indicators of
patient prognosis. Multiple studies have demonstrated good
outcomes for early-stage cancers with MSI, and combined with
data indicating that MSI cancers may not benefit from 5-FU-based
chemotherapy, it has been proposed that moderate- and high-risk
stage II patients exhibiting an MSI phenotype may forego adjuvant
chemotherapy (Popat et al, 2005; Guastadisegni et al, 2010; Ng and
Schrag, 2010). Conversely, there are emerging data that presence
and extent of CIN are associated with inferior outcomes (Walther
et al, 2008; Mouradov et al, 2013). Mutation in BRAF has been
reported as an indicator of poor prognosis, in particular for
patients with metastatic disease, but this relationship is complex,
because of the strong positive association between BRAF mutation
and MSI (Samowitz et al, 2005; French et al, 2008; Tie et al, 2011;
Lochhead et al, 2013). Accordingly, recent data suggest that BRAF
or KRAS mutation are associated with poor prognosis specifically
in patients with MSS cancers (Phipps et al, 2015; Sinicrope et al,
2015). Evidence for the prognostic values of CIMP, PIK3CA and
TP53 mutation is inconsistent (Munro et al, 2005; Russo et al,
2005; Prenen et al, 2010; Day et al, 2013).
Although mutations in APC have a principal role in CRC
initiation, their relation to outcome remains unclear. Most
previous studies have not found an association between the
presence of APC mutation and prognosis, but these analysed small
patient cohorts, only screened limited regions of the APC gene, and
did not account for prognostically important features such MSI,
CIN, BRAF mutation and tumour location (Dix et al, 1994; Løvig
et al, 2002; Conlin et al, 2005; Hsieh et al, 2005; Meguid et al, 2008;
Chen et al, 2009; Wong, 2010; Birnbaum et al, 2012)
Evaluation of APC prognostic value is further complicated by
the observation that proximal and distal tumours differ substan-
tially in their APC mutation spectra. In general, somatic APC
mutations tend to cluster in codons 1282–1581, the so-called
mutation cluster region, producing truncated proteins retaining
1–3 intact 20 amino-acid repeats (20AARs), functional domains
that are critical for b-catenin regulation (Miyoshi et al, 1992;
Christie et al, 2013). However, when analysed by tumour location,
proximal cancers show a marked enrichment for mutations leaving
2–3 20AARs, while distal cancers show predominance of mutations
leaving 0–1 20AARs, indicating distinct WNT/b-catenin signalling
thresholds for tumourigenesis in these embryologically distinct
regions (Rowan et al, 2000; Albuquerque et al, 2002; Christie et al,
2013). A single prognostic study considered location of APC
mutation and suggested that patients who have lost all b-catenin
binding sites (15- and 20-AARs) of APC may have shorter cancer-
related survival than patients with mutations that have retained
one or more binding sites (Løvig et al, 2002); however, this study
did not consider tumour location.
Here, we examined whether APC mutation presence or
genotype are indicators of patient prognosis when accounting for
tumour location, MSI, CIN, CIMP, KRAS, BRAF, PIK3CA and
TP53 status, analysing the largest CRC cohort (n¼ 746) to date in
which the entire coding region of APC has been sequenced.
We then identified the gene expression signature of APC mutation
status using microarray analysis that could predict disease
outcome. We validated the prognostic value of the APC classifier
using an independent cohort of 206 patients from a publicly
available microarray dataset (GSE39582) (Marisa et al, 2013)
(Supplementary Figure 1).
MATERIALS AND METHODS
Patients. We analysed 746 patients with stages I-IV CRC who had
undergone treatment at the Royal Melbourne Hospital (Parkville,
VIC, Australia), Western Hospital Footscray (Footscray, VIC,
Australia), Royal Adelaide Hospital (Adelaide, SA, Australia) and
St Vincent’s Hospital Sydney (Darlinghurst, NSW, Australia).
Patients with familial polyposis syndromes, ulcerative colitis or
Crohn’s disease-associated CRC were excluded. All patients gave
informed consent, and this study was human research ethics
committee-approved (WEHI HREC 12/19). Clinicopathological
characteristics and pre- and post-operative treatment details were
collected using a multi-site database. Tumours from caecum to
transverse colon were defined as proximal, and those from splenic
flexure to rectum as distal. For patients with early stage disease
(I-III), patient follow-up data were collected prospectively accord-
ing to national guidelines, with 3-monthly clinic visits and testing
for carcinoembryonic antigen levels, 12-monthly computed
tomography scans of the chest, abdomen and pelvis for 2 years
after diagnosis, and then 6-monthly clinic visits and carcinoem-
bryonic antigen testing until 5 years from diagnosis. For patients
with stage IV cancer, standard follow-up was with imaging every
8–9 weeks while patients remained on active therapy. Clinical
follow-up while on active therapy was on a 4-weekly basis.
Mutation detection. Mutations in APC (entire coding region),
KRAS (codons 12, 13 and 61), BRAF (V600E), PIK3CA (exons 9
and 20) and TP53 (exons 4 to 9) have been determined previously
(Christie et al, 2013; Day et al, 2013). Briefly, DNA was extracted
from macrodissected tumour and matched normal tissues, and
Sanger sequencing performed in both orientations on a 3730xl
DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Any
detected mutations were confirmed by resequencing of tumour and
matched normal DNA from new PCR product.
Microsatellite instability, CIN and loss of heterozygosity
assessment. Microsatellite instability status was defined using
the Bethesda five-marker microsatellite panel (Boland et al, 1998).
Microsatellite instability was considered present if instability was
seen atX2 markers. Tumour CIN status and loss of heterozygosity
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at APC have been determined previously using single nucleotide
polymorphism microarray analysis (Human 610-Quad BeadChip,
Illumina, San Diego, CA, USA) on tumour and matched normal
DNA samples and OncoSNP software (Isis Innovations, Oxford,
UK) (Yau et al, 2010; Christie et al, 2013; Mouradov et al, 2013).
CpG island methylator phenotype analysis. Tumour CIMP data
have been reported based on MethyLight real-time PCR for the
IGF2, SOCS1, RUNX3, CACNA1G and NGN1 marker panel, and
the reference ALU (Day et al, 2013). Tumours with a percentage of
methylated reference value of greater than 10 for X3 CIMP
markers were classified as CIMP-high (CIMP-H), those with 1–2
methylated markers as CIMP-low (CIMP-L), and 0 methylated
markers as CIMP-0.
Microarray analysis. Gene expression profiles were determined
for 52 MSS proximal colon cancers using the Affymetrix (Santa
Clara, CA, USA) GeneChip Human Exon 1.0 ST Array version 2
according to the manufacturer recommendations. The microarray
data have been deposited in the Gene Expression Omnibus
database (GSE63624). Data were normalised using the Robust
Multi-array Average algorithm (Irizarry et al, 2003) from the
Affymetrix Power Tools software, the normalised data were log
transformed (base 2) and adjusted for a batch effect using the
ComBat algorithm (Johnson et al, 2007). Probe sets that were not
expressed or probe sets that showed a low variability across
samples were excluded. Expression values were required to be
greater than the median of all expression measurements in at least
25% of samples, with an interquartile range across samples on the
log2 scale of greater than 0.5. Genes mapping to sex chromosomes
were excluded because cases were not matched by gender. In
addition, only probes for genes that were also represented on the
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays were
considered to enable cross-referencing across these platforms.
Gene signature for APC mutation status. The Limma algorithm
(Smyth, 2004) was used to rank gene probes associated with
APC-wt status in our set of 52 MSS proximal colon cancers, with
the top-ranked probe for each gene retained for classifier
construction. We then identified the gene signature that could
best classify APC-wt status using a linear kernel nu-support vector
machine (SVM) algorithm (Chang and Lin, 2001) and 10-fold
cross-validation, evaluating sets of 2–100 gene probes, selecting
equal numbers of Limma top-ranked upregulated and down-
regulated candidates. The expression data were mean-centred and
scaled to a mean of zero and a standard deviation of one for each
gene probe entered into the algorithm. The significance of
classification accuracy was evaluated using permutation testing.
First, the accuracy of the optimised discriminating classifier was
measured by 500 times repeated 10-fold cross-validation. Then,
class labels of the samples were permutated 10 000 times, obtaining
a new signature and calculating the 10-fold cross-validation
accuracy for each permutated data set. Finally, the random chance
of obtaining a signature with higher accuracy than the optimised
discriminating classifier was determined.
Validation of prognostic capability of APC gene signature in an
independent dataset. We validated the prognostic capability of
the APC gene signature using a publicly available independent
microarray dataset on stages I to IV CRCs (GSE39582) (Marisa
et al, 2013). Raw data were Robust Multi-array Average -
normalised and batch-corrected using the ComBat algorithm,
and restricted to proximal tumours with available outcome data
(n¼ 206). For genes with multiple alternative probes, those with
the largest variance across samples were selected. Gene probe data
were mean-centred and scaled, and the SVM model used to predict
APC-wt status.
Statistical analysis. Statistical analyses were conducted using the
statistical computing software R (The R Development Core Team,
2013). Differences between groups were assessed using the
Kruskal-Wallis test for continuous variables and Fisher’s exact
test for categorical variables. Odds ratios (ORs) and 95%
confidence intervals (CI) were obtained from Fisher’s exact test
calculations. Outcome analyses were performed for overall survival
(OS) and recurrence-free survival (RFS) from date of surgery,
censored at 5 years. Patients who had received radiotherapy or
were stage IV and had undergone additional surgery for metastases
were excluded. Univariate survival distributions were compared
using the log-rank test. Cox proportional hazards models were
used to estimate survival distributions and hazard ratios for
multivariate analyses, adjusting for gender, age at diagnosis,
tumour stage and treatment; to facilitate comparisons between
multiple APC-wt/-mt tumour groups, hazard ratios were retrieved
for all pairwise combinations of reference states. Comparisons
between models with and without inclusion of specific molecular
variables were made using the likelihood ratio test and the Aikake
Information Criterion. Complete case analysis was used for all
statistical calculations. Statistical analyses were two-sided and
considered significant if Po0.05.
RESULTS
Clinicopathological and molecular features of CRC patients. In
the cohort of 746 patients, the median age at presentation was
70 years and 55% were male (Table 1). Seventy cancers were stage
I, 229 stage II, 347 stage III and 100 stage IV; 315 were from the
proximal colon, 242 from the distal colon and 189 from the
rectum. Clinical follow-up information was available for 685
patients for OS. For patients with stages I-III CRC, RFS data were
available for 415 cases. The median duration of follow-up was
47 months for OS, and 37 months for RFS. Among the 685 patients
with available outcome data, 296 had received standard adjuvant
5-fluorouracil-based chemotherapy (unknown in 33 cases).
The cancers had molecular features that were similar to those
found in other studies (Table 1). Truncating APC mutations were
detected in 68.4% (510 of 746) of tumours, and 31.1% (201 of 627
with available single nucleotide polymorphism array data) showed
loss of heterozygosity at APC. Among the APC-mt cases, 76.7%
(335 of 437) had two hits (2 mutations or 1 mutation and loss of
heterozygosity). The frequencies of mutations in BRAF, KRAS,
PIK3CA and TP53 were 9.0% (67 of 746), 35.1% (262 of 746),
12.5% (93 of 746) and 55.4% (413 of 746), respectively; 73.6% (465
of 632) of tumours were CIN, 13.4% (100 of 746) MSI, 17.3% (85
of 491) CIMP-H and 21.8% (107 of 491) CIMP-L. We confirmed
the established pairwise associations between MSI, CIN and
specific gene mutations. Microsatellite instability displayed a strong
direct association with BRAF mutation (OR¼ 13.0), and a strong
inverse association with TP53 mutation (OR¼ 0.34), while CIN
showed the opposite associations (CIN/BRAF OR¼ 0.20; CIN/TP53
OR¼ 7.8). KRAS and BRAF mutations were mutually exclusive
(OR¼ 0), while KRAS mutation exhibited positive associations with
PIK3CA mutation (OR¼ 2.4) and CIMP-L (OR¼ 1.8 as compared
with CIMP-0) (Po0.012 for all comparisons).
Proximal APC-wt/MSS tumours exhibit inferior prognosis. We
tested whether overall APC mutation status (wild-type vs mutated)
was associated with patient prognosis when accounting for tumour
MSI status and location, and adjusting for gender, age at diagnosis,
tumour stage and treatment. Among patients with MSS tumours,
APC-wt proximal cancers showed significantly inferior prognosis
as compared with APC-mt proximal, APC-wt distal and APC-mt
distal cancers for OS and RFS (OS HRX1.79, Pp0.015; RFS
HRX1.88, Pp0.026) (Figure 1, Table 2A), and this was retained
APC mutation prognostic value in colon cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.296 981
when restricted to stage II and III cancers (OS HRX1.79,
Pp0.029; RFS HRX1.81, Pp0.038) (Supplementary Table 1A).
Accordingly, a multivariate model with an APC-tumour location
interaction term provided a significantly better fit of the survival
data as compared with a model with APC status and tumour
location but without the interaction term (OS, P¼ 0.043; RFS,
P¼ 0.011, likelihood ratio test). We found no evidence for
differential outcomes between APC-mt/MSS proximal, APC-wt/
MSS distal and APC-mt/MSS distal tumours (Figure 1, Table 2A,
Supplementary Table 1A for stage II and III cancers).
No prognostic value of APC mutation in MSI tumours. Among
patients with MSI cancers, testing for association between APC
mutation status and prognosis was restricted to proximal cases
owing to the low prevalence of MSI in distal tumours (n¼ 16). In
contrast to MSS proximal cancers, the adverse prognostic influence
of APC-wt status was lost in MSI proximal cancers (n¼ 75) with
similar OS and RFS for wild-type and mutated tumours (multi-
variate OS, P¼ 0.859; RFS, P¼ 0.779, Figure 1, Table 2B,
Supplementary Table 1B for stage II and III cancers).
Compared with MSI proximal cancers, APC-wt/MSS proximal
tumours showed significantly poorer survival (OS, HR¼ 2.05,
P¼ 0.022; RFS, HR¼ 3.34, P¼ 0.005). Microsatellite instability
proximal tumours further exhibited a trend to improved outcomes
as compared with APC-mt/MSS proximal cancers, although this
was not statistically significant (OS, HR¼ 0.88, P¼ 0.656; RFS,
HR¼ 0.59, P¼ 0.185) (Figure 2A, Table 3A). These trends were
retained when restricting the analysis to stage II and III cancers
(Supplementary Table 2A).
APC mutation genotype does not provide additional prognostic
information. Given the different APC mutation spectra in
proximal and distal tumours (Albuquerque et al, 2010; Christie
et al, 2013), we examined whether classification of tumours by APC
mutation genotype had additional prognostic value. Among
patients with APC-mt/MSS cancers, outcomes were similar across
tumour locations irrespective of whether truncating APC muta-
tions left 0 or X1 15AARs required for b-catenin binding, or
whether the mutations left 0-1 or 2-3 20AARs associated with
residual b-catenin binding/regulatory activity (PX0.169 for all
comparisons, Supplementary Table 3A and B). Further, no
outcome differences were apparent when considering the number
of hits in APC with one exception: proximal tumours with 1 hit in
APC showed a tendency to better OS as compared with distal
tumours with 1 hit in APC (HR¼ 0.37, P¼ 0.049), however, this
trend was not observed for RFS (P¼ 0.246; Supplementary
Table 3C). We did not explore APC genotypes in MSI CRCs
owing to low sample numbers per group.
APC prognostic value in the context of other molecular
changes. The prognostic value of APC status in proximal MSS
tumours was evaluated against other molecular changes. Single-
variable models with BRAF, CIN, CIMP-H, KRAS, PIK3CA or
TP53 status were compared with models with addition of APC
status and vice versa using the likelihood ratio test. In all
comparisons, APC mutation was found to be the strongest
indicator of outcome: addition of APC status significantly
improved all OS and RFS models with CIMP, BRAF, KRAS,
PIK3CA or TP53 or CIN status (Pp0.036 for all comparisons),
whereas addition of the latter molecular variables to models with
APC status did not significantly improve model fit (Table 4).
Accordingly, direct comparison of models with either APC
mutation or the relevant molecular feature of interest using the
Akaike Information Criterion favoured the model with the APC
mutation in all cases (Table 4).
APC gene signature in MSS proximal tumours. For 52 patients
with MSS proximal colon cancer, including 35 APC-mt patients,
we were able to obtain sufficient tumour RNA of high quality for
Table 1. Characteristics of 746 patients with colorectal cancer
according to APC mutation status
APC-wt APC-mt
n ¼ 746 236 (31.6) 510 (68.4) P
Age, years 744 235 509
Mean ± s.d. 69.1±11.3 69.6±11.7 68.9±11.2 0.317
Median 70 70 70
Range 25.0–99.0 25.0–99.0 33.0–93.0
Unknown 2
Sex 746 236 510
Male 413 (55.4) 109 (26.4) 304 (73.6) o0.001*
Female 333 (44.6) 127 (38.1) 206 (61.9)
Stage 746 236 510
I 70 (9.4) 15 (21.4) 55 (78.6) 0.080
II 229 (30.7) 67 (29.3) 162 (70.7)
III 347 (46.5) 124 (35.7) 223 (64.3)
IV 100 (13.4) 30 (30.0) 70 (70.0)
Site 746 236 510
Right Colon 315 (42.2) 131 (41.6) 184 (58.4) o0.001*
Left colon 242 (32.4) 51 (21.1) 191 (78.9)
Rectum 189 (25.3) 54 (28.6) 135 (71.4)
Differentiation 718 221 497
Well/
Moderate
596 (83.0) 162 (27.2) 434 (72.8) o0.001*
Poor 122 (17.0) 59 (48.4) 63 (51.6)
Unknown 28 15 13
Mucinous 737 231 506
No 577 (78.3) 154 (26.7) 423 (73.3) o0.001*
Yes 160 (21.7) 77 (48.1) 83 (51.9)
Unknown 9 5 4
MSI status 746 236 510
MSS 646 (86.6) 167 (25.9) 479 (74.1) o0.001*
MSI 100 (13.4) 69 (69.0) 31 (31.0)
CIMP status 491 140 351
CIMP0 299 (60.9) 55 (18.4) 244 (81.6) o0.001*
CIMPL 107 (21.8) 25 (23.4) 82 (76.6)
CIMPH 85 (17.3) 60 (70.6) 25 (29.4)
Unknown 255 96 159
BRAF 746 236 510
No 679 (91.0) 183 (27.0) 496 (73.0) o0.001*
Yes 67 (9.0) 53 (79.1) 14 (20.9)
KRAS 746 236 510
No 484 (64.9) 185 (38.2) 299 (61.8) o0.001*
Yes 262 (35.1) 51 (19.5) 211 (80.5)
PIK3CA 746 236 510
No 653 (87.5) 214 (32.8) 439 (67.2) 0.095
Yes 93 (12.5) 22 (23.7) 71 (76.3)
TP53 746 236 510
No 333 (44.6) 143 (42.9) 190 (57.1) o0.001*
Yes 413 (55.4) 93 (22.5) 320 (77.5)
CIN status 632 191 441
CIN 167 (26.4) 86 (51.5) 81 (48.5) o0.001*
CINþ 465 (73.6) 105 (22.6) 360 (77.4)
Unknown 114 45 69
Abbreviations: CIN¼ chromosomal instability; CIMP¼CpG island methylator phenotype;
MSI¼microsatellite instability; MSS¼microsatellite stable. Row percentages are given in
parentheses and column percentages are given in square brackets. *Po0.05.
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microarray analysis. Using class-comparison analysis, we ranked
genes by significance of differential expression between APC-wt
and APC-mt patients. A SVM with 10-fold cross-validation was
used to identify the gene signature that could best classify APC-wt
status, with a classifier comprising the top-ranked 18 upregulated
and 18 downregulated gene probes achieving the highest cross-
validation prediction accuracy (95.8%) (Supplementary Figure 2,
Supplementary Table 4). Using these 36 discriminating genes, two-
way clustering and principal component analysis separated
APC-wt and APC-mt patients (Supplementary Figure 3). To
further evaluate the SVM model, we re-trained the model using
10 000 random permutations of the APC mutation data. None of
these permutations yielded equal or superior 10-fold cross-
validation prediction accuracy to that of the trained model,
yielding a false discovery rate less than 10 4. APC-wt gene
signature tumours exhibited statistically significantly worse
survival than APC-mt gene signature tumours, as was observed
when considering APC mutation status determined by Sanger
sequencing (Supplementary Figure 4).
Validation of prognostic capability of APC-wt gene signature in
an independent cohort of proximal colon cancers. We applied
the APC-wt gene signature to an independent microarray dataset
on 206 stage I-IV proximal colon cancers by Marisa et al (2013)
(GSE39582). Consistent with findings in our cohort, patients with
APC-wt-like gene signature MSS tumours showed significantly
poorer OS and RFS than those with APC-mt-like gene signature
MSS tumours and MSI tumours (OS HRX2.50, Pp0.010; RFS
HRX2.14, Pp0.025) (Figure 2B, Table 3B, Supplementary
Table 2B when restricting to stage II and III cancers). There was
no significant difference in outcome by APC class for MSI cancers
(PX0.375 for OS and RFS).
Proximal APC-wt/MSS tumours exhibit features of the sessile
serrated pathway. Given the differences in prognosis among MSS
CRCs by APC status and tumour location, we tested whether these
were reflected at the pathological and molecular level. In pairwise
comparisons between tumour groups (Figure 3, Supplementary
Table 5), the poor prognosis APC-wt/MSS cancers of the proximal
colon (n¼ 70) consistently showed associations with features of the
sessile serrated pathway including poor differentiation, CIMP-H
and BRAF mutation (Pp0.016 for all comparisons), and to a lesser
extent mucinous histology (Pp0.058) and female gender
(Pp0.085, Figure 3A). APC-mt/MSS distal cancers (n¼ 318)
displayed the expected classic adenoma-carcinoma pathway
features such as TP53 mutation and CIN (Pp0.020 for all
comparisons, Figure 3D), while APC-mt/MSS proximal cancers
(n¼ 161) showed association with KRAS mutation (Po0.001 for
all comparisons) and to a lesser extent with PIK3CA mutation
(Pp0.054 for all comparisons), hallmarks of the alternate pathway
(Figure 3B). APC-wt/MSS distal cancers (n¼ 97) showed no
consistently outstanding characteristics, although some tendency
A Microsatellite stable colorectal cancer
B Microsatellite unstable, proximal colon cancer
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Figure 1. Kaplan-Meier curves of OS and RFS (A) for patients with MSS colorectal cancer, and (B) for patients with MSI proximal colon cancer,
according to APC mutation status and tumour location. Abbreviations: Dist, distal; Prox, proximal.
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towards features of the sessile serrated pathway was noted when
compared with APC-mt/MSS distal cancers (mucinous histology,
CIMP-H and BRAF mutation; Pp0.009 for all comparisons).
However, these differences were much less pronounced than for
MSS/APC-wt proximal cancers (Figure 3C).
In contrast, among good prognosis MSI proximal cancers
(n¼ 82), for which the APC prognostic value was attenuated, no
significant differences were apparent by APC status
(Supplementary Table 6). When MSI proximal cancers were
compared with the four groups of MSS cancers, these most closely
resembled the poor prognosis APC-wt/MSS proximal group,
exhibiting an overrepresentation of sessile serrated pathway
features such as female gender, CIMP-H, BRAF mutation, poor
differentiation and mucinous histology (Figure 3E, Supplementary
Table 5). However, MSI proximal cancers differed from all four
groups in showing little CIN and a tendency to present at earlier
tumour stages. Associations for MSI distal cancers were not
investigated owing to the small sample size (n¼ 16).
DISCUSSION
Prognostic, pathological and molecular features of CRC, including
APC mutation spectra, are well-established to differ between
proximal and distal tumours and between MSS and MSI cases
(Meguid et al, 2008; Albuquerque et al, 2010; Wong, 2010;
Sinicrope and Sargent, 2012; Christie et al, 2013). In this study, the
largest survey of the prognostic value of APC mutation to date, we
have found evidence that APC status shows differential outcome
associations across these tumour subgroups: APC-wt/MSS prox-
imal tumours had inferior OS and RFS as compared with APC-mt/
MSS proximal, APC-wt/MSS distal and APC-mt/MSS distal
tumours, which showed similar outcomes. The prognostic value
of APC mutation was lost in the MSI tumours of the proximal
colon, which had the most favourable prognosis overall. Notably,
attenuation of marker prognostic value in MSI cancers has
previously been reported for BRAF mutation and CIMP (Ward
et al, 2003; Samowitz et al, 2005; Ogino et al, 2012). Poor prognosis
of APC-wt/MSS proximal tumours was validated in an indepen-
dent patient cohort (Marisa et al, 2013) using a predictor of
APC-wt status from microarray expression data. Most previous
studies evaluating APC mutation status have not identified a
relationship with prognosis (Dix et al, 1994; Conlin et al, 2005;
Hsieh et al, 2005; Chen et al, 2009; Birnbaum et al, 2012).
However, these studies did not consider CRC groups by tumour
location and MSI status, likely precluded by their smaller sample
sizes (n¼ 100–218), and only performed mutation screening for
limited regions of the APC gene. These differences in study design
and size would have reduced the power to detect tumour-
subgroup-specific outcome associations.
Differences in tumour prognostic behaviours by APC mutation,
location and MSI status were strongly supported by differences at
the pathological and molecular level (Supplementary Figure 5). The
poor prognosis APC-wt/MSS proximal cancers were specifically
associated with characteristics of the sessile serrated neoplasia
pathway including female gender, poor differentiation, mucinous
histology, CIMP-H and BRAF mutation (Leggett and Whitehall,
2010; Snover, 2011; Bettington et al, 2013, 2014). In contrast,
APC-mt/MSS proximal cancers showed features of the alternate
pathway (KRAS and PIK3CA mutation) (Leggett and Whitehall,
2010; Day et al, 2013). APC-mt/MSS distal cancers showed features
of the classic adenoma-carcinoma pathway (TP53 mutation and
CIN) (Fearon and Vogelstein, 1990), whereas APC-wt/MSS distal
cancers had no consistently outstanding features. CpG island
methylator phenotype-L, which has been associated with the
alternate pathway in some studies (Leggett and Whitehall, 2010),
was not overrepresented in APC-mt/MSS proximal cancers,
although a positive association between CIMP-L and KRAS
mutation was apparent for the entire cohort.
Among MSI cancers of the proximal colon, for which the
prognostic value of APCmutation was attenuated, pathological and
molecular features accordingly also did not differ by APC status.
Overall, MSI proximal cancers showed the expected serrated
pathway features (female gender, poor differentiation, mucinous
histology, CIMP-H and BRAF mutation), similar to the poor
prognosis proximal APC-wt/MSS group, but differed in showing
little CIN and presentation at earlier tumour stages.
Table 2A. Cox proportional-hazards analyses of OS and RFS
(A) for patients with microsatellite stable (MSS) colorectal
cancer, and (B) for patients with microsatellite unstable (MS)
proximal colon cancer, according to APC mutation status and
tumour location; (2A) Microsatellite stable (MSS) colorectal
cancer
Overall survival Recurrence-free survival
HR (95% CI) P HR (95% CI) P
APC-wt/Prox vs
APC-mt/Prox
1.79 (1.12–2.85) 0.015* 1.99 (1.08–3.65) 0.026*
APC-wt/Prox vs
APC-wt/Dist
2.01 (1.17–3.43) 0.011* 2.71 (1.39–5.28) 0.003*
APC-wt/Prox vs
APC-mt/Dist
1.84 (1.22–2.78) 0.004* 1.88 (1.13–3.15) 0.016*
APC-mt/Prox vs
APC-wt/Dist
1.12 (0.67–1.87) 0.655 1.36 (0.73–2.54) 0.329
APC-mt/Prox vs
APC-mt/Dist
1.03 (0.71–1.49) 0.876 0.95 (0.60–1.50) 0.814
APC-wt/Dist vs
APC-mt/Dist
0.92 (0.58–1.45) 0.710 0.69 (0.40–1.19) 0.186
Age (Decades) 1.32 (1.12–1.55) o0.001* 0.93 (0.79–1.09) 0.386
Gender (Female
vs Male)
0.77 (0.57–1.04) 0.089 0.66 (0.46–0.95) 0.024*
Stage II vs I 1.03 (0.46–2.30) 0.938 1.88 (0.54–6.50) 0.320
Stage III vs I 3.33 (1.56–7.10) 0.002* 9.23 (2.78–30.65) o0.001*
Stage IV vs I 9.62 (4.33–21.36) o0.001*
Chemotherapy
(Yes vs No)
0.82 (0.57–1.17) 0.270 0.68 (0.43–1.09) 0.107
Events/N 189/561 129/351
Abbreviations: CI¼ confidence interval; Dist¼distal; HR¼ hazard ratio; OS¼overall
survival; Prox¼proximal; RFS¼ recurrence-free survival. To facilitate comparisons between
APC wild-type/mutated tumour groups, hazard ratios are presented for all pairwise
combinations of reference states.
Table 2B. (B) Microsatellite unstable (MSI) proximal colon
cancer
Overall survival Recurrence-free survival
HR (95% CI) P HR (95% CI) P
APC-wt v
APC-mt
0.90 (0.27–2.96) 0.859 1.26 (0.25–6.50) 0.779
Age (Decades) 2.37 (1.30–4.34) 0.005* 0.95 (0.40–2.25) 0.900
Gender (Female
vs Male)
1.06 (0.31–3.59) 0.924 1.58 (0.32–7.80) 0.576
Stage III vs I/IIa 0.95 (0.31–2.90) 0.933 3.36 (0.62–18.30) 0.161
Stage IV vs I/IIa 5.54 (0.38–81.75) 0.213
Chemotherapy
(Yes vs No)
2.10 (0.47–9.37) 0.330 0.25 (0.03–1.99) 0.189
Events/N 17/75 9/53
Abbreviations: CI¼ confidence interval; Dist¼distal; HR¼ hazard ratio.
aCombined stages I/II referent owing to small sample number. *Po0.05.
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The prognostic value of APC mutation status in MSS proximal
cancers was not explained by correlation with other tumour
molecular features such as CIN, CIMP, BRAF, KRAS, PIK3CA or
TP53 status. This is particularly notable for CIN, BRAF and KRAS
mutation, which have been linked to inferior prognosis in MSS
tumours (Tie et al, 2011; Pai et al, 2012; Lochhead et al, 2013;
Sinicrope et al, 2015). Instead, our data suggest a more general
association between tumour sessile serrated pathway features and
poor prognosis, which is supported by recent gene expression-
based studies. Using microarray analysis to create a gene
expression classifier for BRAF-mutated CRCs, Popovici et al
(2012) identified a group of cancers including but not restricted to
BRAF-mutated tumours which showed poor prognosis, proximal
location and mucinous histology, consistent with serrated pathway
characteristics. Similarly, De Sousa et al (2013) used multiple
microarray datasets to identify a CRC subgroup displaying a sessile
serrated adenoma-like gene expression signature and inferior
prognosis as compared with cancers with MSI- or CIN-associated
signatures. A recent molecular profiling study has further reported
poor prognosis for MSS or MSI-low, CIMP-positive, BRAF
mutated, KRAS wild-type CRCs, which likely have significant
overlap with the APC-wt/MSS proximal subtype defined in our
study (Phipps et al, 2015).
Methylation at the APC promoter resulting in gene silencing has
been suggested as a potential alternative mechanism to APC
mutation (Arnold et al, 2004). Using DNA methylation array and
RNA-Seq data for 215 CRCs reported by The Cancer Genome
Atlas Network, neither promoter hypermethylation nor reduced
gene expression were inversely associated with APC mutation
when considering all cases or the subset of MSS proximal cancers
(Supplementary Figure 6) (Network TCGA, 2012). These results
are consistent with our previous observation that APC promoter
hypermethylation does not substitute for truncating mutations
(Segditsas et al, 2008).
Interestingly, AXIN2 and RNF43 were the most differentially
expressed genes by APCmutation status in proximal MSS tumours,
with both showing reduced expression in the APC-wt tumours.
AXIN2 is a component of the central b-catenin destruction
complex, while RNF43 is a transmembrane E3 ligase involved in
removing WNT receptors from the cell surface (Jho et al, 2002;
de Lau et al, 2014). AXIN2 and RNF43 are themselves WNT target
genes and constitute negative WNT feedback loops, suggesting that
their downregulation may be an alternative to APC mutation
causing aberrant WNT pathway activation. AXIN2 and RNF43 are
frequently mutated in MSI CRCs (Liu et al, 2000; Giannakis et al,
2014), and AXIN2 silencing by promoter hypermethylation has
been observed in MSI cancers and sessile serrated adenomas (Muto
et al, 2014). Furthermore, AXIN2 and RNF43 were found in the
Popovici et al (2012) signature for BRAF-mutated CRC and the
De Sousa et al (2013) gene signatures for CRC classification.
It has been suggested that APC-mutated cancers may show
differential outcomes depending on mutation location within the
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Figure 2. Kaplan-Meier curves of OS and RFS (A) for patients with proximal colon cancer, according to APC mutation and microsatellite
instability status (discovery cohort), and (B) for patients with proximal colon cancer, according to APC gene signature and microsatellite
instability status (validation cohort, GSE39582 (Marisa et al, 2013)). Abbreviations: MSS/MSI, microsatellite stable/unstable.
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gene, with patients who have lost all b-catenin binding sites having
shorter cancer-related survival than patients who have retained one
or more binding sites (Løvig et al, 2002). We did not find evidence
of outcome differences by the number of intact b-catenin binding
sites or when comparing tumours with one or two detected hits.
While the number of intact b-catenin binding sites appears to be
important for tumour initiation, with different ‘just-right’ mutation
spectra in the embryologically distinct proximal and distal colon
(Albuquerque et al, 2010; Christie et al, 2013), APC mutation
genotypes appear to have less influence on disease progression.
Although further large cohort studies will be required to validate
our findings, our data suggest a potential role for joint MSI
and APC testing in risk stratification for patients with CRC.
In particular, more aggressive investigation and therapy may be
indicated for patients with poor prognosis APC-wt/MSS proximal
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Figure 3. Comparison of clinicopathological and molecular characteristics between colorectal cancer groups defined by APC mutation status,
microsatellite instability and tumour location. Odds ratios (circles) and 95% confidence intervals (lines) for (A) APC-wt/MSS proximal cancers,
(B) APC-mt/MSS proximal cancers, (C) APC-wt/MSS distal cancers, (D) APC-mt/MSS distal cancers, relative to each other. (E) Comparison of MSI
proximal cancers to the four MSS tumour groups. Abbreviations: CIN chromosomal instability; CIMP, CpG island methylator phenotype; MSS/MSI,
microsatellite stable/unstable.
Table 3A. Cox proportional-hazards analyses of OS and RFS (A)
for patients with proximal colon cancer, according to APC
mutation status and microsatellite instability (discovery cohort);
and (B) for patients with proximal colon cancer, according to
APC gene signature and microsatellite instability (validation
cohort, GSE39582 (Marisa et al, 2013)); (A) Discovery cohort
Overall survival Recurrence-free survival
HR (95% CI) P HR (95% CI) P
MSI vs APC-mt/
MSS
0.88 (0.49–1.57) 0.656 0.59 (0.27–1.29) 0.185
APC-wt/MSS/
vs MSI
2.05 (1.11–3.77) 0.022* 3.34 (1.45–7.68) 0.005*
APC-wt/MSS vs
APC-mt/MSS
1.79 (1.11–2.88) 0.016* 1.97 (1.06–3.63) 0.031*
Age (Decades) 1.41 (1.09–1.82) 0.009* 1.08 (0.81–1.45) 0.588
Gender (Female
vs Male)
0.92 (0.60–1.42) 0.718 0.93 (0.54–1.60) 0.794
Stage II vs I 1.85 (0.43–8.06) 0.412 1.19 (0.25–5.68) 0.824
Stage III vs I 5.04 (1.16–21.82) 0.030* 5.84 (1.26–27.04) 0.024*
Stage IV vs I 19.21 (4.25–86.76) o0.001*
Chemotherapy
(Yes vs No)
1.03 (0.60–1.76) 0.919 0.91 (0.44–1.88) 0.807
Events/N 91/282 55/182
Abbreviations: CI¼ confidence interval; HR¼hazard ratio; MSI¼microsatellite instability;
MSS¼microsatellite stable; OS¼overall survival; RFS¼ recurrence-free survival. Analyses
are adjusted for gender, age at diagnosis, tumour stage and treatment. To facilitate
comparisons between APC wild-type/mutated tumour groups, hazard ratios are presented
for all pairwise combinations of reference states.
Table 3B. (B) Validation cohort
Overall survival Recurrence-free survival
HR (95% CI) P HR (95% CI) P
MSI vs APC-mt/
MSS
1.21 (0.63–2.34) 0.569 0.70 (0.32–1.54) 0.375
APC-wt/MSS/
vs MSI
2.50 (1.25–4.98) 0.010* 3.06 (1.34–6.98) 0.008*
APC-wt/MSS vs
APC-mt/MSS
3.02 (1.67–5.47) o0.001* 2.14 (1.10–4.18) 0.025*
Age (Decades) 1.45 (1.15–1.83) 0.002* 1.12 (0.87–1.44) 0.374
Gender (Female
vs Male)
0.37 (0.22–0.63) o0.001* 0.47 (0.26–0.85) 0.012*
Stage II vs I 0.74 (0.22–2.51) 0.630 2.23 (0.30–16.77) 0.437
Stage III vs I 1.17 (0.34–4.06) 0.809 4.21 (0.55–32.46) 0.167
Stage IV vs I 4.86 (1.22–19.34) 0.025*
Chemotherapy
(Yes vs No)
1.26 (0.68–2.32) 0.458 0.89 (0.43–1.82) 0.742
Events/N 65/201 49/185
Abbreviation: CI¼ confidence interval; HR¼ hazard ratio; MSI¼microsatellite instability;
MSS¼microsatellite stable. *Po0.05.
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tumours. As APC is a large gene with mutations occurring
throughout the 5’ two-thirds of the coding sequence, demonstra-
tion of APC-wt status will require substantial sequencing, which
would previously have been impractical for clinical purposes.
However, with the increasing adoption of massively parallel
sequencing in clinical molecular pathology departments, routine
APC sequencing for prognostic purposes will become feasible.
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